[177Lu]Lu-DOTATATE
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracranial Meningioma
Conditions
Intracranial Meningioma
Trial Timeline
Dec 24, 2025 → Aug 1, 2030
NCT ID
NCT06955169About [177Lu]Lu-DOTATATE
[177Lu]Lu-DOTATATE is a phase 2 stage product being developed by Novartis for Intracranial Meningioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06955169. Target conditions include Intracranial Meningioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06955169 | Phase 2 | Recruiting |
Competing Products
6 competing products in Intracranial Meningioma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tirzepatide + Tirzepatide Placebo | Eli Lilly | Approved | 85 |
| Ticagrelor + Aspirin + Rivaroxaban + Aspirin + Clopidogrel + Aspirin | AstraZeneca | Phase 3 | 77 |
| cabazitaxel + lapatinib | Novartis | Phase 2 | 52 |
| Everolimus + Bevacizumab | Novartis | Phase 2 | 52 |
| Methylprednisolone (Injectable Form) + Placebo Injection | Brain Biotech | Approved | 77 |
| Vismodegib + FAK Inhibitor GSK2256098 + Capivasertib + Abemaciclib | Brain Biotech | Phase 2 | 44 |